These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 11772127)

  • 41. Renal effects of sevoflurane during conditions of possible increased risk.
    Artru AA
    J Clin Anesth; 1998 Nov; 10(7):531-8. PubMed ID: 9805692
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro.
    Altuntas TG; Kharasch ED
    Toxicol Appl Pharmacol; 2001 Dec; 177(2):85-93. PubMed ID: 11740907
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cysteine conjugate beta-lyase-dependent biotransformation of the cysteine S-conjugates of the sevoflurane degradation product 2-(fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A).
    Iyer RA; Anders MW
    Chem Res Toxicol; 1997 Jul; 10(7):811-9. PubMed ID: 9250416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose-dependent metabolism of fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A), an anesthetic degradation product, to mercapturic acids and 3,3,3-trifluoro-2-(fluoromethoxy)propanoic acid in rats.
    Kharasch ED; Jubert C; Spracklin DK; Hoffman GM
    Toxicol Appl Pharmacol; 1999 Oct; 160(1):49-59. PubMed ID: 10502502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of the effects of prolonged (>10 hour) low-flow sevoflurane, high-flow sevoflurane, and low-flow isoflurane anaesthesia on hepatorenal function in orthopaedic patients.
    Fukuda H; Kawamoto M; Yuge O; Fujii K
    Anaesth Intensive Care; 2004 Apr; 32(2):210-8. PubMed ID: 15957718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sevoflurane degradation product concentrations with soda lime during prolonged anesthesia.
    Frink EJ; Isner RJ; Malan TP; Morgan SE; Brown EA; Brown BR
    J Clin Anesth; 1994; 6(3):239-42. PubMed ID: 8060632
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Fluoride-induced nephrotoxicity: factor fiction?].
    Nuscheler M; Conzen P; Schwender D; Peter K
    Anaesthesist; 1996 Feb; 45 Suppl 1():S32-40. PubMed ID: 8775101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Compound A concentrations during sevoflurane anesthesia in children.
    Frink EJ; Green WB; Brown EA; Malcomson M; Hammond LC; Valencia FG; Brown BR
    Anesthesiology; 1996 Mar; 84(3):566-71. PubMed ID: 8659785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Kidney function in test subjects: published results and clinical relevance].
    Frink EJ
    Anaesthesist; 1998 Nov; 47 Suppl 1():S33-6. PubMed ID: 9893878
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Renal effects of prolonged sevoflurane anesthesia in Wistar rats].
    Bermejo-Alvarez MA; Rodríguez-Dintén MJ; Reyes I; Brime-Casanueva JI; Martínez-Merino A; Costales M
    Rev Esp Anestesiol Reanim; 1999; 46(6):241-6. PubMed ID: 10439643
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Changing aspects of sevoflurane in paediatric anaesthesia: 1975-99.
    Holzki J; Kretz FJ
    Paediatr Anaesth; 1999; 9(4):283-6. PubMed ID: 10411761
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of cigarette smoking on serum fluoride concentrations and renal function integrity after 1 MAC-h sevoflurane anaesthesia.
    Laisalmi M; Kokki H; Soikkeli A; Markkanen H; Yli-Hankala A; Rosenberg P; Lindgren L
    Acta Anaesthesiol Scand; 2006 Sep; 50(8):982-7. PubMed ID: 16923094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Low-flow and minimal-flow anesthesia with sevoflurane].
    Baum J; Stanke HG
    Anaesthesist; 1998 Nov; 47 Suppl 1():S70-6. PubMed ID: 9893885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low-flow sevoflurane compared with low-flow isoflurane anesthesia in patients with stable renal insufficiency.
    Conzen PF; Kharasch ED; Czerner SF; Artru AA; Reichle FM; Michalowski P; Rooke GA; Weiss BM; Ebert TJ
    Anesthesiology; 2002 Sep; 97(3):578-84. PubMed ID: 12218523
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The compound A concentration in a low-flow anesthesia circuit using the new CO2 absorbent SPHERASORB].
    Obata R; Bito H; Katoh T; Sato S
    Masui; 2000 May; 49(5):504-8. PubMed ID: 10846381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of sevoflurane and isoflurane on renal function and on possible markers of nephrotoxicity.
    Higuchi H; Sumita S; Wada H; Ura T; Ikemoto T; Nakai T; Kanno M; Satoh T
    Anesthesiology; 1998 Aug; 89(2):307-22. PubMed ID: 9710388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Economic and Environmental Considerations During Low Fresh Gas Flow Volatile Agent Administration After Change to a Nonreactive Carbon Dioxide Absorbent.
    Epstein RH; Dexter F; Maguire DP; Agarwalla NK; Gratch DM
    Anesth Analg; 2016 Apr; 122(4):996-1006. PubMed ID: 26735317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Only carbon dioxide absorbents free of both NaOH and KOH do not generate compound A during in vitro closed-system sevoflurane: evaluation of five absorbents.
    Versichelen LF; Bouche MP; Rolly G; Van Bocxlaer JF; Struys MM; De Leenheer AP; Mortier EP
    Anesthesiology; 2001 Sep; 95(3):750-5. PubMed ID: 11575550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Sevoflurane].
    Gilsanz F; Celemín R; Blanc G; Orts MM
    Rev Esp Anestesiol Reanim; 1996; 43(7):243-8. PubMed ID: 8966352
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantification of the degradation products of sevoflurane in two CO2 absorbants during low-flow anesthesia in surgical patients.
    Frink EJ; Malan TP; Morgan SE; Brown EA; Malcomson M; Brown BR
    Anesthesiology; 1992 Dec; 77(6):1064-9. PubMed ID: 1466458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.